How to use and dosing instructions for Teritusumab/Telica

Teritusumab (Teclistamab-cqyv) is an innovative bispecific T-cell engager (bispecific T-cell engager, BiTE), by simultaneously targeting BCMA (B cell maturation antigen) and CD3, activates the patient's own T cells to recognize and eliminate tumor cells. In clinical applications, the administration method and dose design of teritolumab are strictly standardized to ensure efficacy while reducing the risk of immune-related adverse reactions.

During use, Teritusumab is administered by subcutaneous injection, usually in the abdomen, thighs or other appropriate sites. Initial treatment uses an ascending dose regimen designed to gradually activate the immune system while observing the patient's tolerance to the drug. The escalating dose regimen is divided into three steps: the lowest dose of 0.06 mg/kg is given on the first day, an increasing dose of 0.3 mg/kg is given on the fourth day, and then the first therapeutic dose of 1.5 mg/kg is given on the seventh day. Dosage escalations are spaced 2 to 4 days apart and can be delayed up to 7 days to account for possible adverse reactions. All patients need to be hospitalized for 48 hours of observation after completing the escalating dose regimen to ensure early identification and management of potential side effects.

After completing the escalating dose regimen, patients entered a weekly maintenance treatment phase of 1.5 mg/kg once a week until disease progression or unacceptable toxicity. For patients who achieve and maintain complete remission or better for at least 6 months, the dosing frequency can be adjusted to 1.5 mg/kg every two weeks to reduce the medication burden while maintaining stable efficacy. The entire medication process must be strictly implemented in accordance with the guidance of medical staff, including dosage calculation, injection site selection, and monitoring of the patient's clinical response.

This step-by-step dosing strategy of teritusumab embodies the concept of precision immunotherapy, reducing risks such as cytokine release syndrome through incremental doses while ensuring thatT cell activation and anti-tumor effects are maximized. In daily management, patients and caregivers should pay close attention to body temperature, blood pressure and respiratory status, and promptly report any abnormal reactions to medical staff.

Reference materials:https://www.tecvayli.com/